Cryofocus Medtech (Shanghai) (HKG:6922) has obtained approval for its Malignant Stenosis Cryoablation System from China's National Medical Products Administration, a Thursday filing with the Hong Kong bourse said.
The product is a self-developed cryoablation system indicated to ablate malignant airway tumor tissue and reduce the frequency of airway restenosis, according to the medical device company.
Price (HKD): $4.83, Change: $-0.15, Percent Change: -3.01%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.